BridgeBio Stock Rises Following AstraZeneca and Ionis' Failed Heart Drug Trial

BridgeBio's stock surged after its rival, AstraZeneca (AZN.L), announced the failure of a key Phase 3 trial for Wainua in treating ATTR-CM. The news reduced competitive pressure on BridgeBio’s existing heart drug offerings and boosted investor confidence.

By Shuning Zhao Fri, July 10, 2026 at 2:38 AM GMT+3 3 min read · Yahoo Finance · July 9, 2026, 23:38 UTC

BridgeBio Stock Rises Following AstraZeneca and Ionis' Failed Heart Drug Trial

Tickers: $AZN $BBIO

Topics: ATTR-CM biotech competitor failure drug trials

Read the full article at Yahoo Finance

More World news

EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC
Nuwellis Reports Q3 2026 Revenue of $2.2 Million and Improved Operating Loss Motley Fool · November 12, 2026, 18:09 UTC
Nebius Group Reports Strong Revenue Growth Amidst Capacity Delays and Increased Capital Expenditure Motley Fool · November 12, 2026, 18:11 UTC